Localized Renal Cell Carcinoma
Advertisement
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
The standard of care for intermediate to high-risk RCC consists of partial or radical nephrectomy and surveillance.
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.